/Companies

Veralox

acquired by Cadrenal Therapeutics

11 known investors

Find your way into Veralox

Sign up to see every warm intro you have to Veralox

  • Paths you didn't know you had: your email and LinkedIn already hold routes to the Veralox team. We find them for you
  • 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
  • Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Acquired by Cadrenal Therapeutics, Inc. December 2025 · $200K ($200,000 at closing plus assumed liabilities and contingent milestone/royalty payments) · source ↗

Developing novel treatments based on the 12-LOX pathway for immuno-inflammatory diseases.

Investors · 11

Founder mafia

3 people who came through Veralox went on to found or lead other companies.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase ISTTR2020$300K
National Institutes of Health (NIH)National Institutes of HealthPhase I2018$319.1K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

Frequently asked questions

What does Veralox do?
Developing novel treatments based on the 12-LOX pathway for immuno-inflammatory diseases.
Who are Veralox's investors?
Veralox's investors include Alumni Ventures, Hatteras Venture Partners, Pappas Capital, Sanofi Ventures, Alexandria, Genesys Capital, JDRF T1D Fund, NYBC Ventures and 3 more.
Who acquired Veralox?
Veralox was acquired by Cadrenal Therapeutics.